Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. 2011

Gamze Isitman, and Amy W Chung, and Marjon Navis, and Stephen J Kent, and Ivan Stratov
Department of Microbiology and Immunology, University of Melbourne, Victoria 3010, Australia.

Antibody-dependent cellular cytotoxicity (ADCC) may assist in preventing HIV or delaying disease progression. Most prior studies have analysed Env-specific ADCC responses. We hypothesized that effective ADCC-based immunity may target conserved internal viral proteins such as Pol. We analysed the ability overlapping Pol peptides to induce activation of NK cells via ADCC. We prospectively studied ADCC responses in 83 HIV+ subjects followed for 3 years. Pol peptides were commonly targeted by ADCC responses in these chronically infected subjects (in 32 of the 83 subjects). However, Pol-specific ADCC responses declined over time and did not correlate with delayed HIV progression, measured by either baseline CD4 T cells, CD4 T cell loss over time, baseline viral load or the need to start antiretroviral therapy. Although Pol is frequently targeted by ADCC in HIV+ subjects, the strength or specificity of Pol-specific ADCC responses needs to be modulated to be effective in delaying HIV progression.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D054302 pol Gene Products, Human Immunodeficiency Virus Proteins encoded by the POL GENE of the HUMAN IMMUNODEFICIENCY VIRUS. pol Gene Products, HIV,pol Proteins, Human Immunodeficiency Virus
D018791 CD4 Lymphocyte Count The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer. Lymphocyte Count, CD4,T4 Lymphocyte Count,CD4 Cell Counts,CD4 Counts,CD4+ Cell Counts,CD4+ Counts,CD4 Cell Count,CD4 Count,CD4 Lymphocyte Counts,CD4+ Cell Count,CD4+ Count,Count, T4 Lymphocyte,Counts, T4 Lymphocyte,Lymphocyte Count, T4,Lymphocyte Counts, CD4,Lymphocyte Counts, T4,T4 Lymphocyte Counts

Related Publications

Gamze Isitman, and Amy W Chung, and Marjon Navis, and Stephen J Kent, and Ivan Stratov
November 2018, AIDS (London, England),
Gamze Isitman, and Amy W Chung, and Marjon Navis, and Stephen J Kent, and Ivan Stratov
February 2019, ACS infectious diseases,
Gamze Isitman, and Amy W Chung, and Marjon Navis, and Stephen J Kent, and Ivan Stratov
December 1988, Journal of immunological methods,
Gamze Isitman, and Amy W Chung, and Marjon Navis, and Stephen J Kent, and Ivan Stratov
January 1999, Methods in molecular medicine,
Gamze Isitman, and Amy W Chung, and Marjon Navis, and Stephen J Kent, and Ivan Stratov
September 1999, Clinical and diagnostic laboratory immunology,
Gamze Isitman, and Amy W Chung, and Marjon Navis, and Stephen J Kent, and Ivan Stratov
November 2013, Vaccine,
Gamze Isitman, and Amy W Chung, and Marjon Navis, and Stephen J Kent, and Ivan Stratov
December 1996, AIDS research and human retroviruses,
Gamze Isitman, and Amy W Chung, and Marjon Navis, and Stephen J Kent, and Ivan Stratov
May 2022, JCI insight,
Gamze Isitman, and Amy W Chung, and Marjon Navis, and Stephen J Kent, and Ivan Stratov
August 2014, Virology,
Gamze Isitman, and Amy W Chung, and Marjon Navis, and Stephen J Kent, and Ivan Stratov
February 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Copied contents to your clipboard!